 Shares in Hutchmed China Ltd jumped 6.5 after it announced a licensing deal with Takeda Pharmaceutical worth US1.13bn. With an upfront payment of US400mln plus milestones, the agreement allows the Japanese group to develop Hutchmeds cancer treatment, fruquintinib, outside China. 